Yale Bulletin and Calendar

May 20, 2005|Volume 33, Number 28|Three-Week Issue


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Yale launches research on lung cancer with funding from tobacco companies' settlement

Funds paid to states by tobacco companies are now helping to finance Yale research on a treatment for lung cancer.

Scientists at the Yale Cancer Center working on an innovative treatment for Non-Small Cell Lung Cancer (NSCLC) have received one of two grants from the Connecticut Department of Public Health that resulted from Tobacco Master Settlement Funds. As part of a multi-state agreement in 1998, major tobacco companies must allocate state funding for biomedical research projects in the fields of heart disease, cancer and other tobacco-related illnesses.

The proposed project will establish a Phase-I clinical trial using a combination
of transimmunization (a novel form of immunotherapy) and external beam radiation therapy for the treatment of NSCLC that has spread to areas of the body outside of the chest area.

"The award from the Connecticut Department of Public Health for this novel clinical trial will provide the opportunity to rapidly investigate the safety of a new modality in patients with NSCLC," said Dr. Lynn Wilson, associate professor of therapeautic radiology and dermatology at the School of Medicine and the principal investigator for the Phase-I trial. "Transimmunization was developed at Yale and we are on the leading edge of this type of investigation."

Currently the treatment for NSCLC is relatively ineffective; fewer than 15% of patients diagnosed with NSCLC are cured. While many patients receive second- and third-line chemotherapy treatment, the number that substantially benefit is low. The American Cancer Society estimates that 1,850 men and women will die of lung cancer in Connecticut this year, and that 2,000 new cases will be diagnosed. Lung cancer is the leading cause of death from cancer in Connecticut.

In addition to Wilson, the research team at the Yale Cancer Center includes Dr. Michael Girardi, Dr. Lynn Tanoue, Dr. John Murren, Carole Berger, Dr. Harriet Kluger, Dr. Peter Barrett and Kacie Thompson. For more information on the Phase-I trial, contact Thompson at (203) 785-7432.


T H I SW E E K ' SS T O R I E S

Team creates blood test for 'silent killer'

University marks 100 years of 'Pomp and Circumstance'

Yale scientist featured in new stamp series

Twelve honored for strengthening town-gown ties

ENDOWED PROFESSORSHIPS

Krauss named to second term at Silliman

Researchers discover virus' potential to target and kill deadly brain tumor

Yale professors endow teaching and research fund in the history of science

Study shows, when it comes to fish genitalia, size has pros and cons

Two Yale scientists honored with election to the NAS

Six Yale affiliates elected fellows of scholarly society

Beijing conference explored Chinese constitutionalism

New scholarship will help nurture future activist ministers

Yale-IBM computer facility formally dedicated

REUNIONS

Yale launches research on lung cancer . . .

Workshop will explore technology's power to capture . . .

Show features artist's colorful depictions of 'Northern Shores'

Glen Micalizio wins Beckman Young Investigator award . . .

IN MEMORIAM

Campus Notes


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home